Liquidia Corp
Liquidia Corp (LQDA): 4 pipeline candidates · 3 upcoming catalysts · ~13 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
12.9 months
D/E 2.70 · 14% dilution
Lead: Approved
4 candidates
3 upcoming, next in ~1747d
1 buy · 86 sells (180d)
A transparent, data-derived signal for Liquidia Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.1B
Cash
$222.8M
Quarterly Burn
$59.5M
Runway
12.9 mo
Revenue
$132.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| drug application | Approved |
| L606 | Phase 3 |
| LIQ861 | — |
| YUTREPIA | Approved |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
249
Total value held
$2.53B
| Holder | Shares | Value |
|---|---|---|
| farallon capital management llc | 8,656,038 | $326.7M |
| caligan partners lp | 8,118,892 | $306.4M |
| vanguard capital management llc | 5,853,890 | $220.9M |
| blackrock, inc. | 5,489,144 | $207.2M |
| findell capital management llc | 3,552,112 | $134.1M |
| bank of america corp /de/ | 2,287,792 | $86.3M |
| geode capital management, llc | 1,928,969 | $72.8M |
| citadel advisors llc | 1,915,014 | $72.3M |
| state street corp | 1,881,599 | $71.0M |
| susquehanna international group, llp | 1,657,581 | $62.6M |
Showing top 10 of 249 institutional holders of Liquidia Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Liquidia Corp's pipeline?
Liquidia Corp (LQDA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Liquidia Corp's lead drug candidate?
Liquidia Corp's most advanced tracked candidate is drug application (Approved) for PAH and PH-ILD as soon as possible after obtaining final FDA approval.
What is Liquidia Corp's next catalyst?
Liquidia Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostini" — expected March 31, 2031.
What is Liquidia Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Liquidia Corp has approximately 12.9 months of cash runway.
What is Liquidia Corp's market capitalization?
Liquidia Corp's market capitalization is approximately $6.1B.
Get the full picture on Liquidia Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.